Jubilant Ingrevia Reports Strong Financial Growth Amid Debt Collection Challenges in May 2025

Jubilant Ingrevia, a midcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending March 2025. The results, declared on May 13, 2025, indicate a notable shift in the company's evaluation, with its score rising to 20 from 13 over the past three months.
The financial performance showcases several positive trends. Operating Profit (PBDIT) reached its highest level at Rs 146.69 crore, reflecting consistent growth over the last five quarters. The Operating Profit Margin also peaked at 13.95%, indicating enhanced efficiency within the company. Profit Before Tax (PBT) stood at Rs 93.42 crore, marking a significant increase compared to the average of the previous four quarters. Similarly, Profit After Tax (PAT) reached Rs 74.05 crore, demonstrating a robust growth trajectory. Earnings per Share (EPS) also hit a high of Rs 4.68, signaling improved profitability for shareholders.

However, the financial results also highlight a challenge, as the Debtors Turnover Ratio has reached its lowest point in the last ten half-yearly periods, suggesting a slowdown in the pace of settling debts.

For more insights on Jubilant Ingrevia's financial trends and evaluations, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.